Novartis, stressing Beovu safety, matches Eylea in head-to-head diabetic macular edema trial
Novartis is aiming its new eye drug Beovu, a challenger to Regeneron’s Eylea, at another of its rival’s key markets. And amid a raft of safety concerns, it’s being very mindful of which data to share. In a phase 3 head-to-head study, Beovu matched Eylea in terms of the best-corrected vision acuity that patients with diabetic… Read More »